(18.97.14.80)
[ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 10
First page : ( 4668) Last page : ( 4674)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00821.5

Development, In-vitro and In-vivo evaluation of gastro retentive formulations for moxifloxacin hcl

Gunda Raghavendra Kumar1*, Vijayalakshmi A.2, Masilamani K.3

1Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, Tamil Nadu, India-600117

2Department of Pharmacognosy, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, Tamil Nadu, India-600117

3Department of Pharmaceutics, Jaya College of Paramedical Sciences, College of Pharmacy, Thiruninravur, Chennai, Tamil Nadu, India-602024

*Corresponding Author E-mail: raghav.gunda@gmail.com

Online published on 28 October, 2020.

Abstract

The objective of current study is to develop gastro retentive formulation for Moxifloxacin. HCl using various drug release modifiers and performing In-vitro, In-vivo evaluations. Moxifloxacin, novel synthetic fluoro quinolone, antibacterial agent. Floating, Muco Adhesive tablets of Moxifloxacin. HCl were prepared using variable amounts of HPMCK100M, Lannea coromandelica gum (LCG) by direct compression technique, Wet Granulation technique respectively. Amount of release modifiers required to obtain the prolonged release of drug shows impact on objective of the study. Formulations were developed and are checked for pharmacopoeial tests. Results shows that all the formulations were lie within the standard limits. Dissolution parameters of all formulations were subjected to kinetic fitting, various statistical parameters were determined. Formulation GRSOF containing 50mg of HPMCK100M and 50mg of LCG, is the best formulation showing similarity f2=71.734, f1=4.271 with the marketed product (AVELOX). It follows Higuchi’s kinetics, Non-Fickian Diffusion first order kinetics (n= 0.717). In-vivo studies were performed for the GRSOF with 6 healthy rabbits and pharmacokinetic parameters were determined, compared with AVELOX and found that GRSOF produced similar results. GRSOF expected to improve patient compliance by means of providing good clinical outcome.

Top

Keywords

Moxifloxacin. HCl, Gastro retentive, HPMCK100M, Lannea coromandelica gum, In-vitroIn-vivo.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
853,721,137 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.